D.E. Shaw & Co
ATYR

D.E. Shaw & Co’s aTyr Pharma ATYR Stock Holding History

D.E. Shaw & Co’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83,312
Closed -$60.1K – 5157
2025
Q3 		$60.1K Buy
83,312
+68,026
+445% +$308K ﹤0.01% 4388
2025
Q2 		$77.5K Buy
+15,286
New +$60.1K ﹤0.01% 4142
2022
Q2 		– Sell
-18,808
Closed -$101K – 5889
2022
Q1 		$101K Buy
+18,808
New +$107K ﹤0.01% 4995
2016
Q1 		– Sell
-1,055
Closed -$145K – 3860
2015
Q4 		$145K Buy
+1,055
New +$150K ﹤0.01% 3626

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return